Molecular assay to generate expression profile of eight estrogen receptor alpha isoform mRNA copy numbers in picogram amounts of total RNA from breast cancer tissues

Analytical Biochemistry

Volumn 314, Issue 2, 2003, Pages 217-226

  Poola, Indira ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Clinical molecular assay; ER splice variants; ER wild type; Real time PCR; Splice variant mRNA quantification; Splice targeted primers

Indexed keywords

CELL CULTURE; CELL PROLIFERATION; CELLS; DISEASES; HISTOLOGY; POLYMERASE CHAIN REACTION; RNA;

BREAST CANCER; MOLECULAR ASSAYS; REAL-TIME PCR; SPLICE VARIANTS; SPLICE-TARGETED PRIMERS; WILD TYPES;

TISSUE;

AMINO ACID; COMPLEMENTARY RNA; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; PHENYLALANYLALANYLMETHIONINE; PRIMER RNA; SELECTIVE ESTROGEN RECEPTOR MODULATOR; THREONYLALANYLMETHIONYLALANYLARGINYLALANINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; ASSAY; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER PATIENT; CANCER THERAPY; CANCER TISSUE; CONTROLLED STUDY; ESTROGEN ACTIVITY; ESTROGEN RESPONSIVE ELEMENT; HORMONE INHIBITION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION; RNA SPLICING; RNA TRANSCRIPTION; SENSITIVITY AND SPECIFICITY;

EID: 0037443835     PISSN: 00032697     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-2697(02)00614-0     Document Type: Article

References (17)

1. Jamal A., Thomas A., Murry T., Thun M. Cancer Statistics, 2002. CA Cancer J. Clin. 52:2002;23-47.
2. Harris R., Lippman M.E., Veronesi, Willet W. Breast cancer. N. Engl. J. Med. 327:1992;390-395.
3. Poola I., Speirs V. Alternatively spliced estrogen receptor alpha mRNAs is increased in breast cancer tissues. J. Steroid Biochem. Mol. Biol. 78:2001;459-469.
4. Bollig A., Miksicek R.J. An estrogen receptor-α splicing variant mediates both positive and negative effects on gene transcription. Mol. Endocrinol. 14:2000;634-649.
5. Poola I., Clarke R., DeWitty R., Laffell L.D. Functionally active estrogen receptor isoform profiles in the breast tumors of African American women are distinct from profiles in breast tumors of Caucasian women. Cancer. 94:2002;615-623.
6. Fuqua S.A.W., Falette A., McGuire W.L. Sensitive detection of estrogen receptor RNA by Polymerase Chain Reaction assay. J. Natl. Cancer Inst. 82:1990;859-861.
7. Fasco M.J. Quantification of estrogen receptor mRNA and its alternatively spliced variant mRNAs in breast tumor cells and tissues. Anal. Biochem. 245:1997;167-178.
8. Poola I., Williams D.M., Koduri S., Ramprakash J., Taylor R.E., Hankins W.D. Quantitation of estrogen receptor mRNA copy numbers in breast cancer cell lines and tumors. Anal. Biochem. 258:1998;209-215.
9. Koduri S., Poola I. Quantitation of alternatively spliced estrogen receptor alpha mRNAs as separate gene populations. Steroids. 66:2001;17-23.
10. Koduri S., Fuqua S.A.W., Poola I. Alterations in the estrogen receptor alpha mRNA in the breast tumors of African American women. J. Cancer Res. Clin. Oncol. 126:2000;291-297.
11. Poola I., Abraham J., Liu A. Estrogen receptor beta splice variant mRNAs are differentially altered during breast carcinogenesis. J. Steroid Biochem. Mol. Biol. 82:2002;169-179.
12. Poola I., Koduri S., Chatra S., Clarke R. Identification of twenty alternatively spliced estrogen receptor alpha mRNAs in breast cancer cell lines and tumors using splice targeted primer approach. J. Steroid Biochem. Mol. Biol. 72:2000;249-258.
13. Poola I., Abraham J., Baldwin K. Identification of ten alternatively spliced Estrogen receptor beta mRNAs in human ovary, breast, bone and uterus tissues: Alternative splicing of. ERα mRNA is distinct from that of estrogen receptor beta FEBS Lett. 516:2002;133-138.
14. Green S., Walter P., Kumar V., Krust A., Bornert J.-M., Argos P.et al. Human estrogen receptor cDNA: sequence, expression, and homology to v-erb-A. Nature. 320:1986;134-139.
15. Williams D.M., Koduri S., Li Z., Hankins W.D., Poola I. Primer design strategies for the amplification of alternatively spliced molecules. Anal. Biochem. 271:1999;194-197.
16. Brunner N., Frandsen T.L., Holst-Hansen C., Bei M., Thompson E.W., Lippman M.E., Clarke R. MCF-7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant which remains sensitive to the steroidal antiestrogen, ICI 182,780. Cancer Res. 53:1993;3229-3232.
17. Brtinner N., Boysen B., Jirus S., Skaar T.C., Holst-Hansen C., Lippman J., Frandsen T., Sprang-Thomsen M., Fuqua S.A.W., Clarke R. MCF7/LCC9 (1997): An antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res. 57:1997;3486-3493.